We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the Pediatric Preclinical Testing Program.
- Authors
Houghton, Peter J; Kurmasheva, Raushan T; Kolb, E Anders; Wu, Jianrong; Gorlick, Richard; Maris, John M; Smith, Malcolm A
- Abstract
TAK-701 is a humanized antibody that binds hepatocyte growth factor (HGF), thus suppressing c-Met transduced signaling and c-Met dependent proliferation and migration of tumor cells. Six childhood solid tumor xenografts were selected for evaluating TAK-701 based on immunochemical detection of HGF/c-Met autocrine signaling [i.e., pMet(Tyr1349) and HGF positive]. TAK-701 was tested using a dose of 30 mg/kg administered by the intraperitoneal (IP) route twice weekly for 4 weeks. TAK-701 did not induce significant differences in EFS distribution in treated tumors compared to control tumors. Objective responses were not observed in any of the tested solid tumor xenografts.
- Publication
Pediatric blood & cancer, 2014, Vol 61, Issue 2, p380
- ISSN
1545-5017
- Publication type
Journal Article
- DOI
10.1002/pbc.24756